Is Insulin sensitizers good

Insulin sensitizers in insulin resistance in type 2 diabetes, patients using insulin sensitizers in the end it really good?
Insulin sensitizer for the crowd:
Insulin resistance is commonly found in type 2 diabetes is the major risk factors for type 2 diabetes. Therefore, the drug treatment of type 2 diabetes should be cause, for its focus on improving insulin resistance. Especially for obese patients with type 2 diabetes, insulin resistance, heavier, more appropriate for insulin sensitizers. Relatively short for the main course of insulin resistance in patients with type 2 diabetes, insulin sensitizers monotherapy can receive a better effect, the effect of maintenance therapy is also very good. Research has shown that early in type 2 diabetes, rosiglitazone treatment of type 2 diabetes blood sugar long-term compliance to provide the benefits. If type 2 diabetes duration of longer length, not only insulin resistance, endogenous islet function is also relatively poor, you need a combination of oral hypoglycemic drugs. Can be combined sulfonylurea and non-sulfonylurea insulin secretagogue and metformin. Rosiglitazone recommended dose of 8 mg / day, the recommended dose of pioglitazone 15 to 45 mg / day.
Tip: The insulin sensitizer, only the body cells to increase insulin sensitivity, and only play a role in the case of surviving islet B cell function, not for the absolute lack of insulin in patients with type 1 diabetes.
Adverse reactions of the insulin sensitizer
Thiazole TZDs may cause weight gain and peripheral edema. Edema rate of 4% to 6%, while the incidence of placebo or other hypoglycemic drug treatment group edema 1% to 2%. Edema may induce heart failure. The FDA in the warning in the prescribing information. TZDs for patients with previous heart failure prescription thiazoles, should be carefully considered. Therefore proposed to be bad for the elderly and heart function, avoid the use of these drugs. Thiazolidine TZDs treatment caused a mild dilution anemia is more common, but may not have clinical significance. Another reported that those drugs can cause bone loss in patients older women, the limbs increase in the incidence of fractures. Therefore, the fracture risk in female patients in the choice of antidiabetic drugs should be fully consider the adverse effects of thiazole TZDs